

## Zambia Support for Rotavirus Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Zambia			
<b>2. Grant number:</b> 17-ZMB-13b-X			
<b>3. Date of Decision Letter:</b> 7 April 2017			
<b>4. Date of the Partnership Framework Agreement:</b> 22 October 2014			
<b>5. Programme title:</b> New Vaccine Support (NVS), Rotavirus Routine			
<b>6. Vaccine type:</b> Rotavirus			
<b>7. Requested product presentation and formulation of vaccine:</b> Rotavirus, 2 dose(s) schedule			
<b>8. Programme duration<sup>1</sup>:</b> 2013 - 2017			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2013-2016	2017	Total <sup>2</sup>
Programme Budget (US\$)	US\$ 8,923,115 <sup>3</sup>	US\$2,359,000	US\$11,282,115
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable			
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>			
Type of supplies to be purchased with Gavi funds in each year	2013-2016	2017	
Number of Rotavirus vaccines doses		1,048,500	
Annual Amounts (US\$)	US\$ 8,923,115 <sup>5</sup>	US\$2,359,000	
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
<b>13. Self-procurement:</b> Not applicable			
<b>14. Co-financing obligations:</b> Reference code: 17-ZMB-13b-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

Type of supplies to be purchased with Country funds in each year	2017						
Number of vaccine doses	156,000						
Number of AD syringes							
Number of re-constitution syringes							
Number of safety boxes							
Value of vaccine doses (US\$)	US\$340,255						
Total co-financing payments (US\$) (including freight)	US\$349,500						
<b>15. Operational support for campaigns: Not applicable</b>							
<b>16. Additional reporting requirements: Not applicable</b>							
<table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>May</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>	Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat	
Reports and other information	Due dates						
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May						
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat						
<b>17. Financial clarifications: Not applicable</b>							
18. Other conditions: The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.							

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
7 April 2017